Core Viewpoint - Guojin Securities maintains a "buy" rating for Juzi Bio (02367), projecting EPS for 2025-2027 to be 2.40/2.93/3.54 HKD, with corresponding PE ratios of 23/19/16 times, indicating confidence in the company's product matrix and recovery in sales growth post-public sentiment impact [1][2]. Group 1 - Juzi Holding currently holds approximately 54.26% of the company's shares and plans to increase its stake by at least 200 million HKD within 3-6 months, reflecting strong confidence in the company's future [2]. - The company aims to enhance brand building, channel expansion, and regulatory approvals, focusing on increasing R&D investment for medical device products and meeting diverse market needs [2][3]. Group 2 - The company will intensify marketing efforts for its main brands and incubate new brands to elevate its skincare business, with notable products like collagen sticks and the focus cream showing promising growth [3]. - Juzi Bio plans to initiate commercialization preparations for three categories of medical devices, emphasizing market education and training to support its second growth curve [3].